ACR Convergence 2024

November 14-19, 2024. Washington, DC.

View by Number View by Title View Sessions

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 0285

Anti-THSD7A Antibodies Are Not Broadly Associated with IgG4-Related Disease or IgG4-Related Membranous Nephropathy
Abstract Number: 0256

Anti-TNF Therapy as a Potential Risk of Leishmania Infections
Abstract Number: 0442

Anti-U1-RNP Related Pregnancy Loss in Systemic Lupus Erythematosus
Abstract Number: 1575

Anti-U1RNP Antibodies Are Associated with a Distinct Clinical Phenotype and a Worse Survival in Patients with Systemic Sclerosis
Abstract Number: 0918

Anti-VISTA Antibody Suppresses Neutrophil-mediated Inflammation
Abstract Number: 2522

Anticoagulant Treatment May Decrease the Relapse Rate in Pulmonary Arterial Involvement of Behçet’s Disease When Added After the First Event
Abstract Number: 0732

Antineutrophil Cytoplasmic Antibodies and Associated Vasculitis According to Clinical Phenotypes: A Single-Center Retrospective Cohort Study
Abstract Number: 1603

Antineutrophil Cytoplasmic Autoantibody Levels in Patients in the Avacopan Phase 3 Trial
Abstract Number: 0988

Antinuclear Antibody Positivity and Its Diagnostic Implications for Rheumatic Diseases in Dermatology Patients: A Comprehensive Single Center Analysis
Abstract Number: 1419

Antiphospholipid Antibodies and Hypercoagulable Events in Patients with Sjogren’s Syndrome
Abstract Number: 1267

Antiphospholipid Antibody-related Clinical Manifestations Presenting During Childhood versus Adulthood: Descriptive Results from the AntiPhospholipid Syndrome Alliance for Clinical Trials and InternatiOnal Networking (APS ACTION) Clinical Database and Repository (“Registry”)
Abstract Number: 1645

Antisynthetase Autoantibodies Disrupt the Function of Their Target Aminoacyl-tRNA Synthetases in Muscle Cells
Abstract Number: 0915

APOH Locus Associated with Higher Anti-Beta-2-Glycoprotein 1 Antibody Levels Paradoxically Protects Against Venous Thromboembolism
Abstract Number: 2097

Application of Machine Learning Methods to Predict the Risk of Rapid Pain Progression in Patients with Knee OA. Study Using Patients from the OAI and PROCOAC
Abstract Number: 0510

Applying Machine Learning Tools for Personalized Healthcare: Predicting Responses to Biologics in Rheumatoid Patients Through Comorbidity and Blood Test Analysis

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].